LogoThe Incretin Space
Login
Subscribe
LogoThe Incretin Space
Gallery

The Incretin Space

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretins in medicine

Written by

The Incretin Space

Most Recent

ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron

Jul 2, 2026

ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron

Orals, Triples, Biologics and even more data from ADA 2026

Read more
arrow-right
Eloralintide + Tirzepatide = Bariatric Surgery results!

Jul 1, 2026

Eloralintide + Tirzepatide = Bariatric Surgery results!

New phase 1b data shows incredible weight loss

Read more
arrow-right
ADA Conference 2026: CagriSema & Survodutide

Jun 19, 2026

ADA Conference 2026: CagriSema & Survodutide

A tale of dual agonists, glucagon or amylin, who wins the insulin sensitivity race?

Read more
arrow-right
ADA 2026: Retatrutide Revolution

Jun 9, 2026

ADA 2026: Retatrutide Revolution

A paradigm shift in diabetes and obesity arrives!

Read more
arrow-right
ADA Conference 2026 Preview

May 29, 2026

ADA Conference 2026 Preview

The Super Bowl Conference for diabetes and incretins!

Read more
arrow-right
Triumphant! Retatrutide matches bariatric surgery outcomes

May 21, 2026

Triumphant! Retatrutide matches bariatric surgery outcomes

Triumph 1 trial led to 19-30% weight loss depending on dose and time on trial.

Read more
arrow-right
Maintaining a plateau

May 14, 2026

Maintaining a plateau

Surmount-Maintain and Attain-Maintain trials finally show us what GLP-1 weight maintenance can look like

Read more
arrow-right
Taming the fires

Apr 30, 2026

Taming the fires

The anti-inflammatory benefits of GLP-1 explored

Read more
arrow-right

Archive

GLP-1

+3

ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron

Jul 2, 2026

•

14 min read

ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron

Orals, Triples, Biologics and even more data from ADA 2026

David W
David W

GLP-1

+4

Eloralintide + Tirzepatide = Bariatric Surgery results!

Jul 1, 2026

•

5 min read

Eloralintide + Tirzepatide = Bariatric Surgery results!

New phase 1b data shows incredible weight loss

David W
David W

GLP-1

+2

ADA Conference 2026: CagriSema & Survodutide

Jun 19, 2026

•

18 min read

ADA Conference 2026: CagriSema & Survodutide

A tale of dual agonists, glucagon or amylin, who wins the insulin sensitivity race?

David W
David W

GLP-1

+3

ADA 2026: Retatrutide Revolution

Jun 9, 2026

•

12 min read

ADA 2026: Retatrutide Revolution

A paradigm shift in diabetes and obesity arrives!

GLP-1

+6

ADA Conference 2026 Preview

May 29, 2026

•

10 min read

ADA Conference 2026 Preview

The Super Bowl Conference for diabetes and incretins!

GLP-1

+3

Triumphant! Retatrutide matches bariatric surgery outcomes

May 21, 2026

•

4 min read

Triumphant! Retatrutide matches bariatric surgery outcomes

Triumph 1 trial led to 19-30% weight loss depending on dose and time on trial.

Maintaining a plateau

May 14, 2026

•

9 min read

Maintaining a plateau

Surmount-Maintain and Attain-Maintain trials finally show us what GLP-1 weight maintenance can look like

GLP-1

Taming the fires

Apr 30, 2026

•

9 min read

Taming the fires

The anti-inflammatory benefits of GLP-1 explored

GLP-1

+1

ACHIEVEment Unlocked!

Apr 16, 2026

•

2 min read

ACHIEVEment Unlocked!

Orforglipron reduces the risk of cardiovascular events and all cause death in diabetic patients

The Incretin Space

The Incretin Space

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretin in medicine


Home

© 2026 The Incretin Space.
beehiivPowered by beehiiv